Stock listing

Larimar Therapeutics, Inc.

Selected listing: A2P5PP · LS · EUR · DE

Larimar Therapeutics, Inc. (Lang & Schwarz: A2P5PP), Health Technology. Latest release Sep 29, 2026: Larimar Therapeutics Strengthens Executive Leadership…

A2P5PP:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A2P5PP
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Larimar Therapeutics, Inc.

Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer

September 28, 2026

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

August 4, 2026

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

June 29, 2026

Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia

June 26, 2026

Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update

May 14, 2026

All Larimar Therapeutics, Inc. news →

Research Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. company profile

View the public company page for Larimar Therapeutics, Inc. on 6ix.

Larimar Therapeutics, Inc. news

Read company news and market updates connected to Larimar Therapeutics, Inc..

Larimar Therapeutics, Inc. investor events

Find investor webinars, events, and replay context for Larimar Therapeutics, Inc..